Patients with locally advanced or metastatic hormone-sensitive prostate cancer who received docetaxel and abiraterone acetate plus prednisone or prednisolone and standard of care androgen deprivation therapy had superior patient-reported quality of life compared with patients who received docetaxel plus ADT, although the improvement narrowly missed the predefined value for clinical significance.
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.
This segment delves into targeting the androgen receptor pathway and conquering treatment resistance for potential breakthroughs in managing advanced prostate cancer.
Expert insights into the evolving therapeutic landscape for early-stage breast cancers, emphasizing targeted therapies and genomic testing for personalized treatment paradigms.
Sarah E. S. Leary, MD, MS, discusses the FDA approval of tovorafenib for pediatric patients with relapsed/refractory, BRAF-mutant low-grade glioma.
OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.
Raj Singh, MD, discusses the use of stereotactic body radiation therapy and stereotactic radiosurgery in the treatment of patients with lung cancer.
The FDA granted accelerated approval to tovorafenib for pediatric patients relapsed/refractory low-grade glioma with a BRAF fusion/rearrangement or a BRAF V600 mutation.
Debu Tripathy, MD, highlights the potential role and significance of vepdegestrant in pretreated ER-positive/HER2-negative breast cancer.
The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR)–positive GEP-NETs.
Health Canada has approved subcutaneous atezolizumab for use in patients with lung cancer, breast cancer, and hepatocellular carcinoma.
